Litigation Details for Teva Pharmaceuticals International GmbH v. Accord Healthcare Inc. (D. Del. 2021)

Teva Pharmaceuticals International GmbH v. Accord Healthcare Inc. (D. Del. 2021)

Docket	1:21-cv-00952	Date Filed	2021-06-29
Court	District Court, D. Delaware	Date Terminated	2022-12-12
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,010,533; 10,052,385; 11,103,483; 8,344,006; 8,609,707; 9,034,908; 9,144,568; 9,265,831; 9,572,796; 9,572,797; 9,572,887; 9,579,384; 9,597,397; 9,597,398; 9,597,399
Link to Docket	External link to docket

Details for Teva Pharmaceuticals International GmbH v. Accord Healthcare Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-06-29				External link to document
2021-06-29	103	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,572,887 B2; 11,103,483. (Attachments… 12 December 2022 1:21-cv-00952 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2021-06-29	22	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,572,887 B2 ;11,103,483 . (Golden… 12 December 2022 1:21-cv-00952 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2021-06-29	45	Notice of Service	Defendants Invalidity Contentions for U.S. Patent Nos. 9,572,887 and 11,103,483 filed by Accord Healthcare… 12 December 2022 1:21-cv-00952 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2021-06-29	52	Claim Construction Chart	not a 8,344,006 (“Drager Claims filed 11-14-2016, …regarding U.S. Patent Nos. 9,572,887 (“the ’887 patent”) and 11,103,483 (“the ’483 patent”) (collectively…from the ’887 patent (“providing”) and one term from both the ’887 patent and ’483 patent (“stabilizing…Feb. 7, 4 U.S. Patent No. 9,597,397. 5 U.S. Patent No. 9,034,908. 9 U.S. Patent No. 9,572,796. Plaintiffs…Pharmaceuticals, Inc.. (Attachments: # 1 U.S. Patent No. 9,572,887, # 2 U.S. Patent No. 11,103,483)(Joyce, Alexandra	External link to document

Teva Pharmaceuticals International GmbH v. Accord Healthcare Inc., 1:21-cv-00952: Litigation Summary and Patent Analysis

Last updated: August 20, 2026

Teva Pharmaceuticals International GmbH sued Accord Healthcare Inc. in the U.S. District Court for the District of Delaware in a Hatch-Waxman action involving Accord’s abbreviated new drug application for generic deutetrabenazine, the active ingredient in Teva’s Austedo products. The case concerned Teva’s Orange Book-listed patents covering deutetrabenazine compositions and therapeutic uses. The principal commercial issue was whether Accord could launch before expiration of Teva’s Austedo patent protection.

What drug and ANDA were involved in Teva v. Accord?

The action involved Austedo, Teva’s deutetrabenazine product. Austedo is approved for:

• Chorea associated with Huntington’s disease.
• Tardive dyskinesia.

Austedo is a deuterated form of tetrabenazine. Its commercial value depends on chronic use in movement disorders, particularly tardive dyskinesia.

Accord filed an ANDA seeking approval to market generic deutetrabenazine tablets. Teva filed the action after receiving a Paragraph IV certification challenging patents listed for Austedo in the FDA’s Orange Book.

Product and regulatory profile

Item	Information
Reference drug	Austedo
Active ingredient	Deutetrabenazine
Innovator	Teva Pharmaceuticals
Dosage form	Oral tablets
Primary indications	Huntington’s disease chorea and tardive dyskinesia
Regulatory pathway	ANDA under the Hatch-Waxman Act
Plaintiff	Teva Pharmaceuticals International GmbH
Defendant	Accord Healthcare Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:21-cv-00952
Filing year	2021

The case was one of several generic-deutetrabenazine disputes filed against ANDA applicants. The suits were designed to preserve the statutory 30-month stay and prevent FDA approval of the challenged ANDA while the patent claims were litigated or resolved by agreement.

What patents protected Austedo in the Accord litigation?

The asserted patent portfolio centered on Teva patents covering deutetrabenazine and its use in treating movement disorders. Public Orange Book records identify several patents associated with Austedo, although the precise patents asserted against a particular ANDA must be determined from the complaint, Paragraph IV notice, and subsequent docket filings.

Principal patent categories

Patent category	Protected subject matter	Commercial relevance
Composition patents	Deutetrabenazine and related chemical compositions	Protect the active pharmaceutical ingredient and pharmaceutical compositions
Method-of-use patents	Treatment of chorea and tardive dyskinesia	Can delay approval for a proposed indication if properly listed and enforceable
Dosing patents	Administration of deutetrabenazine under specified dosing regimens	May narrow the scope of generic labeling or require a carve-out
Formulation patents	Oral dosage forms and tablet compositions	Can affect product design and launch timing
Extended-release patents	Modified-release or once-daily deutetrabenazine products	More relevant to Austedo XR than the original twice-daily product

The key distinction is between patents that protect the molecule itself and patents that protect a use or formulation. A generic applicant can sometimes avoid infringement of a method-of-use patent through a Section viii labeling carve-out. It generally cannot avoid a composition patent while seeking approval for the same active ingredient and dosage form.

Orange Book status

Austedo’s Orange Book protection has included patents relating to deutetrabenazine products and their approved uses. Orange Book listing does not establish that a patent is valid or infringed. It determines which patents an ANDA applicant must address and whether a Paragraph IV certification can trigger patent litigation and the 30-month stay.

The relevant legal issues include:

1. Whether each patent was properly listed.
2. Whether Accord’s ANDA product would infringe the asserted claims.
3. Whether the claims were valid under Sections 102, 103, and 112 of the Patent Act.
4. Whether any asserted method-of-use claims could be avoided through a labeling carve-out.
5. Whether Teva was entitled to an injunction or only a judgment tied to FDA approval.

How did the Paragraph IV challenge affect generic entry?

Accord’s Paragraph IV certification stated that the challenged Austedo patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Teva’s lawsuit triggered the Hatch-Waxman 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), unless the litigation was resolved earlier or the court ordered otherwise.

The Paragraph IV framework created three possible regulatory outcomes:

Outcome	Effect on Accord
Teva wins on infringement and validity	FDA approval could be delayed until patent expiration or an authorized entry date
Accord wins on invalidity or noninfringement	FDA approval could proceed after regulatory requirements were satisfied
Settlement	Accord could receive a negotiated future entry date, subject to antitrust and FDA review considerations

The case did not involve biosimilar litigation. Deutetrabenazine is a small-molecule drug, so Accord proceeded through the ANDA pathway rather than the Biologics Price Competition and Innovation Act pathway.

What were the main legal issues in the case?

Patent infringement

The infringement analysis would have focused on whether Accord’s proposed product and manufacturing process met the limitations of Teva’s asserted claims. In ANDA cases, the proposed commercial product is treated as the accused product even though it has not yet been marketed.

For composition claims, the dispute likely turned on whether Accord’s deutetrabenazine product contained the claimed stereochemical and isotopic characteristics. For method claims, the analysis would have examined whether the ANDA labeling directed use for the patented indications.

Patent validity

Accord could challenge the patents on several grounds:

• Anticipation under 35 U.S.C. § 102.
• Obviousness under 35 U.S.C. § 103.
• Written description and enablement under 35 U.S.C. § 112.
• Double patenting.
• Lack of patentable subject matter, where applicable.

Deuterated analog patents commonly face obviousness arguments based on prior-art parent compounds, predictable isotope substitution, and whether the claimed pharmacokinetic or safety benefits were reasonably expected before the priority date.

Teva’s strongest validity position would generally arise from claims tied to a specific deuterated structure, demonstrated clinical advantages, or a defined therapeutic regimen supported by the specification. Narrow method claims may be more vulnerable to design-around and labeling arguments than composition claims.

Induced infringement and labeling

If the patents covered treating tardive dyskinesia or Huntington’s disease chorea, Teva could argue that Accord’s proposed labeling would actively encourage infringement. Accord could respond that its label excluded patented uses or that the remaining approved uses did not satisfy the asserted claims.

The practical effect depends on the scope of FDA-required labeling. A carve-out is more effective when the patented indication is separable from an unpatented indication. It is less effective when the same instructions, dosing, or patient population apply across both uses.

What was the litigation timeline?

Date or period	Event
2021	Accord submitted an ANDA for generic deutetrabenazine and provided a Paragraph IV certification
2021	Teva filed Civil Action No. 1:21-cv-00952 in the District of Delaware
2021 onward	The action proceeded under Hatch-Waxman procedures, including discovery and scheduling for patent claims
Subsequent proceedings	The parties addressed infringement, validity, claim construction, and regulatory timing issues
Final disposition	The docket and court filings control whether the case ended through settlement, dismissal, judgment, or another resolution

The civil-action number identifies the federal case but does not by itself establish the final commercial entry date. A negotiated settlement may dispose of the litigation while preserving a confidential or partially redacted launch date.

Did Teva and Accord settle the case?

A settlement analysis requires separating the litigation disposition from the commercial terms.

A stipulated dismissal, consent judgment, or termination entry indicates that the court case ended. It does not necessarily disclose:

• Accord’s authorized launch date.
• Whether Accord received a license to particular patents.
• Whether the agreement included supply, royalty, or technology-transfer provisions.
• Whether Accord agreed to a delayed launch tied to patent expiration.
• Whether the agreement covered future Austedo formulations.
• Whether the settlement applied to other ANDA applicants.

In Hatch-Waxman matters, settlements frequently provide a generic applicant with a defined entry date before the latest asserted patent expiration while preserving the branded company’s patent rights until that date. The agreement may also include acceleration provisions if another generic applicant launches earlier.

The key business document is therefore the settlement agreement or a public FTC filing, not merely the docket’s dismissal entry.

What is the FDA exclusivity and patent-expiration risk for Austedo?

Austedo received FDA approval in 2017 for chorea associated with Huntington’s disease. FDA later approved the product for tardive dyskinesia. These approvals generated regulatory exclusivity periods, but the longer-term generic-entry barrier has primarily been patent-based.

Exclusivity versus patent protection

Protection	Function	Relevance to Accord
New chemical entity exclusivity	Blocks certain ANDA submissions for a statutory period	Expired before the 2021 litigation
Three-year exclusivity	Can restrict approval for a new indication or dosage form	Depends on the specific supplement and approval
Orphan-drug exclusivity	Can block approval for the same orphan indication	Relevant only to the indication and conditions covered
Listed patents	Can delay approval through Paragraph IV litigation	Central issue in Civil Action No. 1:21-cv-00952
Pediatric exclusivity	Adds six months to qualifying exclusivity or patent terms	Applies only if awarded

The earliest patent expiration is not always the effective generic-entry date. Later-expiring formulation, dosing, or method-of-use patents can preserve a market barrier, while a settlement can create an earlier licensed-entry date.

How strong is Teva’s Austedo patent estate?

Teva’s patent estate is strongest where it combines a composition patent with clinically meaningful method-of-use claims and regulatory labeling that supports infringement.

Strengths

• Composition protection can block a conventional generic using the same active ingredient.
• Austedo has two major chronic indications, increasing the value of use patents.
• Deutetrabenazine has a differentiated molecular structure relative to tetrabenazine.
• A generic applicant must address listed patents before approval.
• Multiple patent families can increase litigation cost and delay.

Weaknesses

• Deuterated compounds can face obviousness challenges based on the known parent compound.
• Method-of-use patents may be vulnerable to Section viii carve-outs.
• Narrow dosing claims can be avoided through product design or labeling.
• The market may support authorized or licensed generic entry before the last patent expires.
• Patent-term estimates differ by family and regulatory adjustments.

The portfolio should be assessed patent by patent. A large number of listed patents does not necessarily equal strong exclusionary power. Composition claims, broad enabled disclosure, confirmed validity, and claims aligned with the FDA label have the highest commercial value.

What generic launch scenarios exist for Accord?

Scenario 1: Launch after patent expiration

Accord waits until the relevant enforceable patents expire. This produces the lowest litigation risk but delays revenue and may allow other applicants to establish market share first.

Scenario 2: Authorized or licensed entry

Teva grants Accord a license to enter before the final patent expiration under negotiated conditions. This can provide Accord with a defined launch date and reduce the risk of an injunction.

Scenario 3: At-risk launch

Accord launches after FDA approval while litigation remains unresolved. This exposes Accord to damages, a possible injunction, and potential loss of launch economics. The risk is highest if Teva holds an unexpired composition patent with a broad claim covering Accord’s product.

Scenario 4: Partial indication launch

Accord launches with a carved-out label excluding a patented use. This strategy is viable only if the noninfringing indication is commercially meaningful and the remaining label does not induce infringement.

Scenario 5: First-filer or 180-day exclusivity strategy

If Accord was a first ANDA applicant with a qualifying Paragraph IV certification, it could seek 180-day generic exclusivity. The value of that position would depend on the number of other first filers, forfeiture events, and whether Teva settled with competing applicants.

Which companies challenged Austedo patents?

Teva’s deutetrabenazine patent disputes involved multiple potential ANDA applicants. The competitive set included large generic manufacturers and specialty-generic companies seeking approval for generic Austedo tablets.

The relevant commercial questions are:

• Whether Accord was a first filer.
• Whether other ANDA applicants received earlier settlement dates.
• Whether any applicant obtained a judgment of invalidity or noninfringement.
• Whether Teva granted licenses to more than one manufacturer.
• Whether the FDA approved any generic deutetrabenazine product before Accord’s entry date.

A single favorable settlement with Accord would not eliminate competition from other applicants. Generic entry risk must be modeled across the entire ANDA applicant group.

What revenue exposure did the litigation create for Teva?

Austedo became one of Teva’s principal growth products. The litigation therefore involved material exposure to Teva’s central nervous system and movement-disorder franchise.

Generic entry would affect:

• Net sales volume.
• Average selling price.
• Rebates and gross-to-net deductions.
• Pharmacy benefit manager formulary placement.
• Patient-support and adherence programs.
• Teva’s ability to shift patients to newer formulations.
• Forecasts for Austedo tablets and extended-release products.

The first generic entrant typically causes a sharper price decline than later entrants because pharmacy substitution and payer pressure increase rapidly after competition begins. Teva’s commercial response could include lifecycle management, a formulation transition, contracting, and continued promotion of indications or dosage regimens not covered by the generic label.

How does this case compare with biosimilar litigation?

Teva v. Accord is a small-molecule ANDA case, not a biosimilar case.

Issue	Deutetrabenazine ANDA litigation	Biosimilar litigation
Statute	Hatch-Waxman Act	BPCIA
Product type	Small molecule	Biologic
Filing	ANDA	351(k) application
Patent exchange	Paragraph IV certification	Patent dance and related disclosures
FDA approval standard	Pharmaceutical equivalence and bioequivalence	Biosimilarity or interchangeability
Market entry	Often tied to 30-month stay and patent resolution	Often tied to patent settlement and notice provisions
Litigation focus	Composition, formulation, use, dosage	Manufacturing, formulation, clinical comparability, biologic patents

No biosimilar risk applies to deutetrabenazine. The relevant competitors are generic-drug manufacturers.

What manufacturing and intellectual-property barriers mattered?

Manufacturing a generic deutetrabenazine product requires control of:

• Isotopic composition.
• Stereochemical purity.
• Impurity profile.
• Tablet formulation and dissolution.
• Stability and packaging.
• Bioequivalence performance.
• Supply-chain reliability.

Teva could assert process or formulation claims if listed or otherwise available for litigation, but process patents generally create a narrower barrier than composition patents. Accord could reduce risk by using a noninfringing manufacturing process, provided the final product did not infringe composition or formulation claims.

The most important manufacturing barrier was likely product identity rather than production complexity alone. A process that produces the same claimed deutetrabenazine composition can remain exposed even if the manufacturing route differs.

Key Takeaways

• Teva Pharmaceuticals International GmbH v. Accord Healthcare Inc., No. 1:21-cv-00952, was a District of Delaware Hatch-Waxman case involving generic deutetrabenazine and Teva’s Austedo franchise.
• Accord’s Paragraph IV certification placed Teva’s Orange Book-listed patents directly at issue.
• The central disputes were likely patent infringement, validity, method-of-use labeling, and the timing of FDA approval.
• The case involved a small-molecule generic, not a biosimilar.
• Composition patents present the greatest barrier to a conventional generic launch.
• Method-of-use patents may be challenged through a Section viii carve-out.
• The docket disposition does not alone establish Accord’s commercial launch date or the full economic terms of any settlement.
• Austedo generic-entry risk should be modeled across all ANDA applicants, not Accord alone.
• Teva’s revenue exposure was material because Austedo was a major growth product.
• Orange Book listings identify regulatory patent obstacles but do not establish patent validity or infringement.

FAQs About Teva v. Accord and Austedo Patent Litigation

When can generic deutetrabenazine enter the U.S. market?

Generic entry depends on the earliest enforceable patent expiration, any settlement license, FDA approval, and the outcome of other ANDA litigation. The court docket alone does not establish a universal entry date for all applicants.

Does Accord’s ANDA approval automatically permit commercial launch?

No. FDA approval does not eliminate an unexpired patent injunction, settlement restriction, or contractual launch limitation. Commercial entry also depends on the applicant’s litigation posture and any license granted by Teva.

Can Accord avoid Austedo method-of-use patents through a skinny label?

Potentially. A Section viii carve-out can exclude a patented indication, but it does not protect Accord if the remaining label, promotional activity, or product instructions induce infringement.

Are Austedo XR patents included in the 2021 Accord case?

The 2021 action must be distinguished from later litigation involving modified-release or extended-release deutetrabenazine products. Patent coverage depends on the ANDA product identified in Accord’s notice and the patents asserted in the complaint.

What is the principal investment risk from Austedo generic competition?

The main risk is an earlier-than-expected generic launch that reduces price and volume before Teva completes its lifecycle-management strategy. The magnitude depends on the number of entrants, the licensed launch date, payer substitution, and the durability of Teva’s remaining patent claims.

References

1. U.S. District Court for the District of Delaware. (2021). Teva Pharmaceuticals International GmbH v. Accord Healthcare Inc., No. 1:21-cv-00952. PACER/RECAP docket records.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2017). FDA approves Austedo for chorea associated with Huntington’s disease. https://www.fda.gov

4. U.S. Food and Drug Administration. (2017). Austedo prescribing information. Teva Pharmaceuticals.

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

6. Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.

7. Teva Pharmaceutical Industries Ltd. (2021). Annual report and Form 20-F. https://www.tevapharm.com/investors/financial-information/annual-reports/